Orchestra Biomed Holdings Stock Price Prediction
| OBIO Stock | 5.57 0.20 3.47% |
Oversold Vs Overbought
49
Oversold | Overbought |
EPS Estimate Next Quarter (0.42) | EPS Estimate Current Year (1.66) | EPS Estimate Next Year (1.95) | Wall Street Target Price 15.6 | EPS Estimate Current Quarter (0.43) |
Using Orchestra BioMed hype-based prediction, you can estimate the value of Orchestra BioMed Holdings from the perspective of Orchestra BioMed response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Orchestra BioMed to buy its stock at a price that has no basis in reality. In that case, they are not buying Orchestra because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Orchestra BioMed after-hype prediction price | USD 5.53 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Orchestra |
Orchestra BioMed After-Hype Price Prediction Density Analysis
As far as predicting the price of Orchestra BioMed at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Orchestra BioMed or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Orchestra BioMed, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Orchestra BioMed Estimiated After-Hype Price Volatility
In the context of predicting Orchestra BioMed's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Orchestra BioMed's historical news coverage. Orchestra BioMed's after-hype downside and upside margins for the prediction period are 0.50 and 10.56, respectively. We have considered Orchestra BioMed's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Orchestra BioMed is slightly risky at this time. Analysis and calculation of next after-hype price of Orchestra BioMed Holdings is based on 3 months time horizon.
Orchestra BioMed Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Orchestra BioMed is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Orchestra BioMed backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Orchestra BioMed, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.11 | 5.03 | 0.04 | 0.00 | 7 Events / Month | 4 Events / Month | In about 7 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
5.57 | 5.53 | 0.72 |
|
Orchestra BioMed Hype Timeline
Orchestra BioMed Holdings is now traded for 5.57. The entity has historical hype elasticity of -0.04, and average elasticity to hype of competition of 0.0. Orchestra is forecasted to decline in value after the next headline, with the price expected to drop to 5.53. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.72%, whereas the daily expected return is now at -0.11%. The volatility of related hype on Orchestra BioMed is about 44711.11%, with the expected price after the next announcement by competition of 5.57. About 22.0% of the company outstanding shares are owned by corporate insiders. The book value of Orchestra BioMed was now reported as 1.22. The company recorded a loss per share of 1.6. Orchestra BioMed Holdings had not issued any dividends in recent years. Given the investment horizon of 90 days the next forecasted press release will be in about 7 days. Check out Orchestra BioMed Basic Forecasting Models to cross-verify your projections.Orchestra BioMed Related Hype Analysis
Having access to credible news sources related to Orchestra BioMed's direct competition is more important than ever and may enhance your ability to predict Orchestra BioMed's future price movements. Getting to know how Orchestra BioMed's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Orchestra BioMed may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| BCE | BCE Inc | (0.38) | 8 per month | 0.00 | (0.32) | 1.53 | (1.83) | 12.47 | |
| CECO | CECO Environmental Corp | (0.73) | 8 per month | 3.20 | 0.04 | 4.73 | (3.36) | 18.98 | |
| IRVDF | Ironveld Plc | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| FIGI | Freedom Internet Group | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| IRDM | Iridium Communications | 0.76 | 6 per month | 2.78 | 0.04 | 3.63 | (4.52) | 17.08 | |
| CENX | Century Aluminum | 0.18 | 7 per month | 2.66 | 0.15 | 6.41 | (4.60) | 24.39 | |
| SPHR | Sphere Entertainment Co | 0.26 | 8 per month | 0.00 | (0.14) | 5.06 | (4.40) | 14.27 | |
| MAANF | Maanshan Iron Steel | 0.00 | 0 per month | 0.00 | 0.12 | 0.00 | 0.00 | 37.69 |
Orchestra BioMed Additional Predictive Modules
Most predictive techniques to examine Orchestra price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Orchestra using various technical indicators. When you analyze Orchestra charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Orchestra BioMed Predictive Indicators
The successful prediction of Orchestra BioMed stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Orchestra BioMed Holdings, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Orchestra BioMed based on analysis of Orchestra BioMed hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Orchestra BioMed's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Orchestra BioMed's related companies. | 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 0.0981 | 0.0811 | 0.0641 | 0.0894 | Days Of Inventory On Hand | 124.72 | 312.86 | 286.51 | 179.55 |
Story Coverage note for Orchestra BioMed
The number of cover stories for Orchestra BioMed depends on current market conditions and Orchestra BioMed's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Orchestra BioMed is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Orchestra BioMed's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Orchestra BioMed Short Properties
Orchestra BioMed's future price predictability will typically decrease when Orchestra BioMed's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Orchestra BioMed Holdings often depends not only on the future outlook of the potential Orchestra BioMed's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Orchestra BioMed's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 33.2 M | |
| Cash And Short Term Investments | 87.6 M |
Check out Orchestra BioMed Basic Forecasting Models to cross-verify your projections. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orchestra BioMed. If investors know Orchestra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orchestra BioMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.60) | Revenue Per Share 0.073 | Quarterly Revenue Growth 1.356 | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Orchestra BioMed Holdings is measured differently than its book value, which is the value of Orchestra that is recorded on the company's balance sheet. Investors also form their own opinion of Orchestra BioMed's value that differs from its market value or its book value, called intrinsic value, which is Orchestra BioMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orchestra BioMed's market value can be influenced by many factors that don't directly affect Orchestra BioMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orchestra BioMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Orchestra BioMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orchestra BioMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.